NetworkNewsBreaks – Silo Pharma Inc. (SILO) Ente
Post# of 138
(Total Views: 182)
Posted On: 03/31/2022 3:11:30 PM
NetworkNewsBreaks – Silo Pharma Inc. (SILO) Enters Agreement to Significantly Advance Technologies ‘Closer to the Clinic’
Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. Silo Pharma today announced its entry into an agreement with Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals. “This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic,” said Eric Weisblum, CEO of Silo Pharma. “These solutions have the potential to enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity. These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They may be used to treat both central nervous system and autoimmune diseases.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. Silo Pharma today announced its entry into an agreement with Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals. “This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic,” said Eric Weisblum, CEO of Silo Pharma. “These solutions have the potential to enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity. These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They may be used to treat both central nervous system and autoimmune diseases.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)